NCT03772249 - Study of Safety and Tolerability of DCR HBVS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 28, 2018

Primary Completion Date

July 12, 2022

Study Completion Date

July 12, 2022

Conditions

Hepatitis B, Chronic

Interventions

DRUG

DCR-HBVS

DCR-HBVS is a synthetic ribonucleic acid interference (RNAi) drug that consists of a double-stranded oligonucleotide conjugated to N-acetyl-D-galactosamine (GalNAc) ligands. DCR-HBVS is a sterile solution of the siRNA (DCR-S219) at a concentration of 195 mg/mL in water for injection (WFI).

DRUG

Placebo for DCR-HBVS

Sterile 9% saline for injection.

Trial Locations (9)

1023

Clinical Site, Auckland

3065

St Vincent's Hospital Melbourne, Fitzroy

3168

Monash Health, Clayton

Unknown

Queen Mary Hospital (The University of Hong Kong), Hong Kong

Middlemore Hospital, Auckland

Seoul National University Hospital, Seoul

Seoul Metropolitan Government - Seoul National University Boramae Medical Center, Soeul

King Culalongkorn Memorial Hospital, Bangkok

Srinagarind Hospital, Khon Kaen

All Listed Sponsors

lead

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

INDUSTRY